The DEA’s stimulant quota revisions for 2024–2025 represent a significant regulatory acknowledgment of rising ADHD treatment needs. However, the 2025 ADHD medication shortage persists due to complex supply-chain, manufacturing, and distribution factors. Ongoing monitoring from ASHP, FDA, and the DEA remains essential as providers and patients navigate disrupted access to critical medications.